Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Beijing, People's Republic of China.
Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.
Int J Womens Health. 2014 May 27;6:547-54. doi: 10.2147/IJWH.S57470. eCollection 2014.
To evaluate the patient satisfaction and health related quality of life (HRQoL) for levonorgestrel-releasing intrauterine system (LNG-IUS) versus conventional medical treatments ([CMTs] combined oral contraceptives, oral progestins, and antifibrinolytics, alone or in combination) in Asian women with heavy menstrual bleeding (HMB).
A total of 647 patients diagnosed with HMB were recruited to this non-interventional study from the eight participating countries in Asia. Patient satisfaction was recorded at the last visit (at 12 months or premature discontinuation). At each visit (at 3, 6, and 12 months), patients completed the menorrhagia multi-attribute scale (MMAS) to assess HRQoL.
A total of 83.5% of patients on the LNG-IUS were "very satisfied" or at least "satisfied" with the therapeutic effect of HMB treatment, compared with 59.2% of patients with CMTs (P<0.05). The mean (± standard deviation) MMAS score increased from 41.4±24.5 to 87.7±21.4 in the LNG-IUS arm, and from 44.1±24.9 to 73.1±25.3 in the CMTs arm. This increase was significantly higher in patients on the LNG-IUS, as compared with those on CMTs (P<0.05). The improvement in HRQoL in both treatment groups correlated with the body mass index of the patient, with larger improvement obtained in women with a higher body mass index.
The majority of women using the LNG-IUS or CMTs for HMB were satisfied with their treatment, and both treatment modalities were associated with significant improvements in HRQoL over time. The improvement was greater with the LNG-IUS, compared with CMTs.
评估左炔诺孕酮宫内缓释系统(LNG-IUS)与传统医学治疗([CMTs] 联合口服避孕药、口服孕激素和抗纤维蛋白溶解剂,单独或联合使用)在亚洲患有月经过多(HMB)的女性中的患者满意度和健康相关生活质量(HRQoL)。
本非干预性研究共招募了来自亚洲 8 个参与国家的 647 名 HMB 确诊患者。在最后一次就诊(12 个月或提前停药时)记录患者满意度。在每次就诊(3、6 和 12 个月时),患者使用月经过多多属性量表(MMAS)评估 HRQoL。
LNG-IUS 组中共有 83.5%的患者对 HMB 治疗的疗效“非常满意”或至少“满意”,而 CMTs 组中这一比例为 59.2%(P<0.05)。LNG-IUS 组的 MMAS 评分从 41.4±24.5 增加到 87.7±21.4,CMTs 组从 44.1±24.9 增加到 73.1±25.3。与 CMTs 组相比,LNG-IUS 组的患者评分增加更为显著(P<0.05)。两组患者的 HRQoL 改善均与患者的体重指数相关,体重指数较高的女性改善更大。
大多数使用 LNG-IUS 或 CMTs 治疗 HMB 的女性对其治疗满意,并且两种治疗方法都随着时间的推移与 HRQoL 的显著改善相关。与 CMTs 相比,LNG-IUS 的改善更大。